Prognia
Drug Database
🇪🇺EU · EMALapsedATC: N03AF04

Exalief(eslicarbazepine acetate)

Epilepsy

Marketing Authorisation Holder: BIAL - Portela Ca, S.A.

EMA Authorisation: 21/04/2009

INN: eslicarbazepine acetate

Indication

Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Exalief — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.